{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:57:56Z","timestamp":1790024276572,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1245\/s10434-025-18409-z","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T19:23:43Z","timestamp":1768245823000},"page":"4668-4678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Surgery for Gastroenteropancreatic Neuroendocrine Tumors with Synchronous Liver Metastasis"],"prefix":"10.1245","volume":"33","author":[{"given":"Tracey","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Luberice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadin","family":"Ghabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay R.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra N.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina M.","family":"Larrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarfraz R.","family":"Akmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa V.","family":"Eade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber Leila","family":"Sarvestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"18409_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.soc.2020.08.001","volume":"30","author":"CG Tran","year":"2021","unstructured":"Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical management of neuroendocrine tumor liver metastases. Surg Oncol Clin North Am. 2021;30:39\u201355. https:\/\/doi.org\/10.1016\/j.soc.2020.08.001.","journal-title":"Surg Oncol Clin North Am."},{"key":"18409_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.gtc.2022.06.002","volume":"51","author":"CJ Fernandes","year":"2022","unstructured":"Fernandes CJ, Leung G, Eads JR, Katona BW. Gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin North Am. 2022;51:625\u201347. https:\/\/doi.org\/10.1016\/j.gtc.2022.06.002.","journal-title":"Gastroenterol Clin North Am."},{"key":"18409_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ags3.12396","volume":"4","author":"K Eto","year":"2020","unstructured":"Eto K, Yoshida N, Iwagami S, Iwatsuki M, Baba H. Surgical treatment for gastrointestinal neuroendocrine tumors. Ann Gastroenterol Surg. 2020;4:652\u20139. https:\/\/doi.org\/10.1002\/ags3.12396.","journal-title":"Ann Gastroenterol Surg."},{"key":"18409_CR4","doi-asserted-by":"publisher","first-page":"14348","DOI":"10.3748\/wjg.v20.i39.14348","volume":"20","author":"SS Alagusundaramoorthy","year":"2014","unstructured":"Alagusundaramoorthy SS, Gedaly R. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol. 2014;20:14348\u201358. https:\/\/doi.org\/10.3748\/wjg.v20.i39.14348.","journal-title":"World J Gastroenterol."},{"key":"18409_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.surg.2018.04.070","volume":"165","author":"AT Scott","year":"2019","unstructured":"Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O\u2019Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165:166\u201375. https:\/\/doi.org\/10.1016\/j.surg.2018.04.070.","journal-title":"Surgery."},{"key":"18409_CR6","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1245\/s10434-020-08787-x","volume":"27","author":"A Gangi","year":"2020","unstructured":"Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol. 2020;27:3270\u201380. https:\/\/doi.org\/10.1245\/s10434-020-08787-x.","journal-title":"Ann Surg Oncol."},{"key":"18409_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.21873\/anticanres.15520","volume":"42","author":"IA Ziogas","year":"2022","unstructured":"Ziogas IA, Schmitz R, Moris D, Vatsaas CJ. The role of surgery for pancreatic neuroendocrine tumors. Anticancer Res. 2022;42:629\u201339. https:\/\/doi.org\/10.21873\/anticanres.15520.","journal-title":"Anticancer Res."},{"key":"18409_CR8","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","volume":"24","author":"M Fairweather","year":"2017","unstructured":"Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, Clancy TE. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24:2319\u201325. https:\/\/doi.org\/10.1245\/s10434-017-5839-x.","journal-title":"Ann Surg Oncol."},{"key":"18409_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000431379","volume":"102","author":"S Partelli","year":"2015","unstructured":"Partelli S, Inama M, Rinke A, et al. Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. Neuroendocrinology. 2015;102:68\u201376. https:\/\/doi.org\/10.1159\/000431379.","journal-title":"Neuroendocrinology."},{"key":"18409_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.21037\/hbsn.2020.04.02","volume":"9","author":"JM Cloyd","year":"2020","unstructured":"Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surg Nutr. 2020;9:440\u201351. https:\/\/doi.org\/10.21037\/hbsn.2020.04.02.","journal-title":"Hepatobiliary Surg Nutr."},{"key":"18409_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/mpa.0000000000000846","volume":"46","author":"JR Howe","year":"2017","unstructured":"Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46:715\u201331. https:\/\/doi.org\/10.1097\/mpa.0000000000000846.","journal-title":"Pancreas."},{"key":"18409_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1053\/j.seminoncol.2018.07.002","volume":"45","author":"XM Keutgen","year":"2018","unstructured":"Keutgen XM, Schadde E, Pommier RF, Halfdanarson TR, Howe JR, Kebebew E. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: a surgeon\u2019s plea to centering attention on the liver. Semin Oncol. 2018;45:232\u20135. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.07.002.","journal-title":"Semin Oncol."},{"key":"18409_CR13","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet."},{"key":"18409_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","volume":"159","author":"JE Maxwell","year":"2016","unstructured":"Maxwell JE, Sherman SK, O\u2019Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy? Surgery. 2016;159:320\u201333. https:\/\/doi.org\/10.1016\/j.surg.2015.05.040.","journal-title":"Surgery."},{"key":"18409_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.surg.2017.05.030","volume":"163","author":"RE Morgan","year":"2018","unstructured":"Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163:218\u201325. https:\/\/doi.org\/10.1016\/j.surg.2017.05.030.","journal-title":"Surgery."},{"key":"18409_CR16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1677\/erc-09-0042","volume":"16","author":"A Ahmed","year":"2009","unstructured":"Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16:885\u201394. https:\/\/doi.org\/10.1677\/erc-09-0042.","journal-title":"Endocr Relat Cancer."},{"key":"18409_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2016.12.032","volume":"224","author":"EA Woltering","year":"2017","unstructured":"Woltering EA, Voros BA, Beyer DT, et al. Aggressive surgical approach to the management of neuroendocrine tumors: a report of 1000 surgical cytoreductions by a single institution. J Am Coll Surg. 2017;224:434\u201347. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2016.12.032.","journal-title":"J Am Coll Surg."},{"key":"18409_CR18","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1245\/s10434-020-09566-4","volume":"28","author":"CG Tran","year":"2021","unstructured":"Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol. 2021;28:2741\u201351. https:\/\/doi.org\/10.1245\/s10434-020-09566-4.","journal-title":"Ann Surg Oncol."},{"key":"18409_CR19","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1245\/s10434-023-14610-0","volume":"31","author":"K S\u00f8reide","year":"2024","unstructured":"S\u00f8reide K, St\u00e4ttner S, Hallet J. Surgery as a principle and technical consideration for primary tumor resection of small bowel neuroendocrine tumors. Ann Surg Oncol. 2024;31:1125\u201337. https:\/\/doi.org\/10.1245\/s10434-023-14610-0.","journal-title":"Ann Surg Oncol."},{"key":"18409_CR20","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1097\/sla.0000000000004647","volume":"276","author":"S Bennett","year":"2022","unstructured":"Bennett S, Coburn N, Law C, et al. Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensity-score matched comparative population-based analysis. Ann Surg. 2022;276:e450\u20138. https:\/\/doi.org\/10.1097\/sla.0000000000004647.","journal-title":"Ann Surg."},{"key":"18409_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13215366","volume":"13","author":"C Touloupas","year":"2021","unstructured":"Touloupas C, Faron M, Hadoux J, et al. Long-term efficacy and assessment of tumor response of transarterial chemoembolization in neuroendocrine liver metastases: a 15-year monocentric experience. Cancers Basel. 2021;13:1. https:\/\/doi.org\/10.3390\/cancers13215366.","journal-title":"Cancers Basel."},{"key":"18409_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med."},{"key":"18409_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0290","volume":"5","author":"S Pusceddu","year":"2022","unstructured":"Pusceddu S, Prinzi N, Tafuto S, et al. Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors. JAMA Netw Open. 2022;5:e220290. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0290.","journal-title":"JAMA Netw Open."},{"key":"18409_CR24","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/jco.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656\u201363. https:\/\/doi.org\/10.1200\/jco.2009.22.8510.","journal-title":"J Clin Oncol."},{"key":"18409_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1316158.","journal-title":"N Engl J Med."},{"key":"18409_CR26","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.2147\/ott.S142087","volume":"10","author":"R Buzzoni","year":"2017","unstructured":"Buzzoni R, Carnaghi C, Strosberg J, et al. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther. 2017;10:5013\u201330. https:\/\/doi.org\/10.2147\/ott.S142087.","journal-title":"Onco Targets Ther."},{"key":"18409_CR27","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.3390\/cancers15184438","volume":"15","author":"AK Clift","year":"2023","unstructured":"Clift AK, Drymousis P, von Roon A, et al. Management of small bowel neuroendocrine tumours: 10 years\u2019 experience at a tertiary referral centre. Cancers. 2023;15:4438.","journal-title":"Cancers."},{"key":"18409_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.surg.2015.05.042","volume":"159","author":"XM Keutgen","year":"2016","unstructured":"Keutgen XM, Nilubol N, Glanville J, et al. Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2016;159:311\u20138. https:\/\/doi.org\/10.1016\/j.surg.2015.05.042.","journal-title":"Surgery."},{"key":"18409_CR29","doi-asserted-by":"publisher","first-page":"79785","DOI":"10.18632\/oncotarget.19523","volume":"8","author":"L Tao","year":"2017","unstructured":"Tao L, Xiu D, Sadula A, et al. Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases. Oncotarget. 2017;8:79785\u201392. https:\/\/doi.org\/10.18632\/oncotarget.19523.","journal-title":"Oncotarget."},{"key":"18409_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejso.2016.09.011","volume":"43","author":"E Bertani","year":"2017","unstructured":"Bertani E, Fazio N, Radice D, et al. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail: a propensity score survival evaluation. Eur J Surg Oncol. 2017;43:372\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2016.09.011.","journal-title":"Eur J Surg Oncol."},{"key":"18409_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/as9.0000000000000151","volume":"3","author":"J Kjaer","year":"2022","unstructured":"Kjaer J, Clancy TE, Thornell A, et al. Benefit of primary tumor resection in stage IV, grade 1 and 2, pancreatic neuroendocrine tumors: a propensity score-matched cohort study. Ann Surg Open. 2022;3:e151. https:\/\/doi.org\/10.1097\/as9.0000000000000151.","journal-title":"Ann Surg Open."},{"key":"18409_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrab062","author":"J Kjaer","year":"2021","unstructured":"Kjaer J, St\u00e5lberg P, Crona J, Welin S, Hellman P, Thornell A, Norlen O. Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases. BJS Open. 2021. https:\/\/doi.org\/10.1093\/bjsopen\/zrab062.","journal-title":"BJS Open."},{"key":"18409_CR33","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/jco.23.01529","volume":"41","author":"JD Rivero","year":"2023","unstructured":"Rivero JD, Perez K, Kennedy EB, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41:5049\u201367. https:\/\/doi.org\/10.1200\/jco.23.01529.","journal-title":"J Clin Oncol."},{"key":"18409_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/jco.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023;41:1359\u201369. https:\/\/doi.org\/10.1200\/jco.22.01013.","journal-title":"J Clin Oncol."},{"key":"18409_CR35","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/mpa.0000000000001597","volume":"49","author":"TR Halfdanarson","year":"2020","unstructured":"Halfdanarson TR, Strosberg JR, Tang L, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49:863\u201381. https:\/\/doi.org\/10.1097\/mpa.0000000000001597.","journal-title":"Pancreas."},{"key":"18409_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/mpa.0000000000001454","volume":"49","author":"JR Howe","year":"2020","unstructured":"Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49:1\u201333. https:\/\/doi.org\/10.1097\/mpa.0000000000001454.","journal-title":"Pancreas."},{"key":"18409_CR37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.surg.2017.11.007","volume":"163","author":"S Partelli","year":"2018","unstructured":"Partelli S, Bertani E, Bartolomei M, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2018;163:761\u20137. https:\/\/doi.org\/10.1016\/j.surg.2017.11.007.","journal-title":"Surgery."},{"key":"18409_CR38","doi-asserted-by":"publisher","first-page":"S703","DOI":"10.1016\/j.annonc.2023.09.719","volume":"34","author":"S Partelli","year":"2023","unstructured":"Partelli S, Landoni L, Bartolomei M, et al. 1186MO: a prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE followed by surgery for pancreatic neuroendocrine tumors (NeoLuPaNET). Ann Oncol. 2023;34:S703. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.719.","journal-title":"Ann Oncol."},{"key":"18409_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/mnm.0000000000000776","volume":"39","author":"S Basu","year":"2018","unstructured":"Basu S, Parghane RV, Ostwal V, Shrikhande SV. Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome? Nucl Med Comm. 2018;39:94\u20135. https:\/\/doi.org\/10.1097\/mnm.0000000000000776.","journal-title":"Nucl Med Comm."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18409-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18409-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18409-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:26:01Z","timestamp":1776255961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18409-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["18409"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18409-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"DISCLOSURE"}}]}}